.jpg "/Content/Upload/Product/Human_ELISA_kits_Diagnocine_1200_1200(284).jpg")
Human pulmonary activation regulated chemokine,PARC ELISA Kit
The Ultimate 1-Stop ELISA Marketplace:
60,000+ ELISA kits Available to Serve Scientists from All Fields of Life Science
Always Powered by Diagnocine for Precision Research.
Most comprehensive buffers, reagents and detection agents are provided with each kit to optimize data output.
All-inclusive format covers everything from sample preparation to signal detection. Every step can be customized and optimized for your precision research.
DiagnoCine Precision buffers and reagents are Made in USA ISO 13485 Certified
Why waste time searching for your ELISA kit when you can get everything in one place? Diagnocine can provide you with all the ELISA needs you have (customized ELISAs also available) on the planet through a single, streamlined ordering process.
* all types of species
* HRP and AP detection
* Low target signal enhancement
* Inquire about a trial version or a customized version
4 core reagents below are included with every order, plus 1 of the 2 detection-specific reagents (matched automatically to your kit type) — 5 components, every time.
+ the 5th component, matched to your kit's detection method:
If you have any questions or need additional information, please call us at 551-245-1033 or email us at support@diagnocine.com. Our team will be happy to assist you.
Universal Compatibility
All buffers and detection reagents work seamlessly across target proteins, bridging the gap in assay consistency.
1-Stop Convenience
Consolidate your lab's purchasing. Source all ELISA needs and experience optimal buffers and reagents in a single shipment.
Enhanced Precision
Designed by scientists for scientists, all components are engineered to deliver sharper results and an optical signal.
Human pulmonary activation regulated chemokine,PARC ELISA Kit
Sandwich quantitative immunoassay for Human pulmonary activation regulated chemokine,PARC in human serum, plasma, cell culture supernates, tissue homogenates available in multiple catalog sizes:
Note: Please send inquiries regarding Trial 24T orders to support@diagnocine.com.
| Uniprot No. | P55774 |
| Species | Homo sapiens (Human) |
| Sample types | serum, plasma, cell culture supernates, tissue homogenates |
| Detection range | 31.25 pg/ml-2000 pg/ml |
| Sensitivity | 7.81 pg/ml |
| Assay time | 1-5h |
| Sample loading volume | 50-100μL |
| Detection wavelength | 450 nm |
| Assay principle | Sandwich (Quantitative) |
| Data analysis | Standard curve + Curve Expert software |
| Research area | Immunology |
| Storage condition | 2-8°C (see protocol for full details) |
| Shipping condition | 4 °C |
| Shelf life | 6 months |
10 business days
Processing + 3-5 days shipping
In Stock : USA
Worldwide shipping available
Antibody capture
450 nm detection
Standard curve
Quantification
In this sandwich ELISA, Human pulmonary activation regulated chemokine,PARC in the sample is captured between a pre-coated capture antibody and a detection antibody. Signal intensity is proportional to analyte concentration. Quantification uses a standard curve fitted with Curve Expert software, covering 31.25 pg/ml-2000 pg/ml with a minimum detectable dose of 7.81 pg/ml.
The ELISA Kit is designed for quantitatively measuring human PARC levels in samples, including serum, plasma, cell culture supernates, or tissue homogenates. It uses the sandwich enzyme immunoassay technique in combination with the enzyme-substrate chromogenic reaction to quantify the analyte in the sample. The color develops positively to the amount of PARC in samples. The color intensity is measured at 450 nm via a microplate reader.
PARC, also known as CCL18, is a chemokine primarily expressed in monocytes, macrophages, and immature dendritic cells and plays a crucial role in immune and inflammation responses. CCL18 attracts lymphocytes and immature dendritic cells and induces collagen deposition by fibroblasts. Recent studies have found that CCL18 is associated with the progression of malignant tumors. It is predominantly derived from breast tumor-associated macrophages (TAMs). Previous data indicate that the CCL18/Nir1 signaling promotes the invasion, metastasis, and EMT of breast cancer cells through the PI3K/Akt/GSK3β/Snail signaling pathway. CCL18 also reduces proliferation in non-small cell lung cancer cells and pre-B acute lymphocytic leukemia cells but enhances proliferation in breast cancer, diffuse large B cell lymphoma, ovarian cancer, osteosarcoma, and urothelial carcinoma.
- PARC activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing. PMID: 28234357
- An increased lung protein expression of PARC in chronic obstructive pulmonary disease patients PMID: 28545096
- Data suggested that CCL18 upregulated Slug expression to promote epithelial-mesenchymal transition (EMT) and stem cell-like features by activating the mTOR pathway in oral cancer. PMID: 28574664
- AMAP1 mediated CCL18-induce activation of NF-kappaB and promoted breast cancer metastasis. PMID: 28834540
- This study study discovered a positive feedback loop between CTGF and CCL18 in hepatocellular carcinoma metastasis. PMID: 28837877
- There was no association between serial CCL18 concentrations with tumor response and overall survival. PMID: 28957436
- Serum C-C motif chemokine ligand 18 (CCL18) was elevated in patients with epithelial ovarian cancer (EOC) and could serve as a new tumor biomarker, which also predicted a poor survival of the patient. PMID: 29036787
- findings suggest that these pulmonary markers could be useful to assess CAP severity and, especially YKL-40 and CCL18 by helping predict CAP caused by atypical pathogens PMID: 29324810
- CCL18 was up-regulated in diffuse large B cell lymphoma and related to poor prognosis PMID: 29504526
- chemokine CCL18 can be a mediator of peritoneal membrane failure associated with peritonitis episodes as well as providing a new potential therapeutic target. PMID: 29850544
- In advanced lung adenocarcinoma, infiltration of CCL18(+) tumor-associated macrophages (TAMs) was increased and higher expression of CCL18 by TAMs was associated with a favorable prognosis in lymph-node positive NSCLC PMID: 29970512
- miR-128 interacts with CCL18 3'UTR, reducing its expression in malignant melanoma. PMID: 30025750
- results of the study indicate that there could be a relationship between the expression of CCL-18 in nasal turbinate mucosa and the severity of allergic rhinitis PMID: 30102123
Intra-assay Precision (Precision within an assay): CV%<8% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Three samples of known concentration were tested twenty times on one plate to assess. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inter-assay Precision (Precision between assays): CV%<10% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Three samples of known concentration were tested in twenty assays to assess. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed. | |||||||||||||
| |||||||||||||
pg/ml | OD1 | OD2 | Average | Corrected | |||||||||
2000 | 2.466 | 2.585 | 2.526 | 2.394 | |||||||||
1000 | 1.991 | 1.944 | 1.968 | 1.836 | |||||||||
500 | 1.482 | 1.567 | 1.525 | 1.393 | |||||||||
250 | 1.213 | 1.130 | 1.172 | 1.040 | |||||||||
125 | 0.832 | 0.900 | 0.866 | 0.734 | |||||||||
62.5 | 0.477 | 0.450 | 0.464 | 0.332 | |||||||||
31.25 | 0.244 | 0.251 | 0.248 | 0.116 | |||||||||
0 | 0.129 | 0.135 | 0.132 |
| |||||||||
To assess the linearity of the assay, samples were spiked with high concentrations of human PARC/CCL18 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay. | |||||||||||||
| Sample | Serum(n=4) | |||||||||||
1:100 | Average % | 91 | |||||||||||
Range % | 87-94 | ||||||||||||
1:200 | Average % | 97 | |||||||||||
Range % | 95-103 | ||||||||||||
1:400 | Average % | 98 | |||||||||||
Range % | 95-102 | ||||||||||||
1:800 | Average % | 93 | |||||||||||
Range % | 91-98 | ||||||||||||
The recovery of human PARC/CCL18 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section. | |||||||||||||
Sample Type | Average % Recovery | Range | |||||||||||
Serum (n=5) | 91 | 87-94 | |||||||||||
EDTA plasma (n=4) | 98 | 95-102 | |||||||||||